Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
Quick Facts
What This Study Found
GLP-1 receptor agonists showed no increased risk of acute pancreatitis (HR 0.56) or biliary disease (HR 1.12) compared to SGLT-2 inhibitors in a population-based study of diabetes and obesity patients.
Key Numbers
Acute pancreatitis: HR 0.56 (95% CI 0.17-1.91). Biliary disease: HR 1.12 (95% CI 0.79-1.58). Population-based study in Valencia, Spain, 2015-2021.
How They Did This
Population-based, propensity-weighted, new user, active comparator cohort study. Compared GLP-1 RA initiators to SGLT-2 inhibitor initiators.
Why This Research Matters
Pancreatitis and gallbladder problems have been safety concerns for GLP-1 drugs. This large real-world comparison against another diabetes drug class found no increased risk, providing reassurance.
What This Study Doesn't Tell Us
Observational design. Wide confidence intervals for pancreatitis suggest limited events. Single Spanish region. Claims-based diagnoses may miss mild cases. Residual confounding possible.
Trust & Context
- Original Title:
- Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
- Published In:
- Gaceta sanitaria, 39, 102444 (2025)
- Authors:
- Robles Cabanillas, Celia, Hurtado Navarro, Isabel, García-Sempere, Aníbal, Llopis-Cardona, Fran, Sánchez-Sáez, Francisco, Rodríguez-Bernal, Clara, Sanfélix-Gimeno, Gabriel
- Database ID:
- RPEP-13279
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13279APA
Robles Cabanillas, Celia; Hurtado Navarro, Isabel; García-Sempere, Aníbal; Llopis-Cardona, Fran; Sánchez-Sáez, Francisco; Rodríguez-Bernal, Clara; Sanfélix-Gimeno, Gabriel. (2025). Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.. Gaceta sanitaria, 39, 102444. https://doi.org/10.1016/j.gaceta.2024.102444
MLA
Robles Cabanillas, Celia, et al. "Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.." Gaceta sanitaria, 2025. https://doi.org/10.1016/j.gaceta.2024.102444
RethinkPeptides
RethinkPeptides Research Database. "Association of glucagon-like peptide-1 receptor agonists wit..." RPEP-13279. Retrieved from https://rethinkpeptides.com/research/robles-2025-association-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.